ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

  • Abstract Number: 1549 • ACR Convergence 2021

    Experience from a Diverse Rheumatology Cohort with COVID-19: Are We Doing Better Than We Expected?

    Michael Grant1, Matas Orentas2, Sobia Hassan1, Sonali Khandelwal1, Donyea Moore3 and Najia Shakoor1, 1Rush University, Chicago, IL, 2RUMC, Chicago, IL, 3Rush University Medical Center, Chicago, IL

    Background/Purpose: The COVID-19 pandemic has been particularly concerning for patients with rheumatologic conditions because they are potentially predisposed to more severe outcomes. Studies have suggested…
  • Abstract Number: 1556 • ACR Convergence 2021

    Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)

    Ines Perez - Sancristobal1, Dalifer Freites1, Leticia Lopez Pedraza2, Maria Paula Alvarez Hernandez1, Jose Ignacio Colomer3, Alfredo Madrid - Garcia2, Benjamin Fernandez1, Cristina Vadillo1, Luis Rodriguez Rodriguez4, Arkaitz Mucientes2, Leticia Leon - Mateos2 and Lydia Abasolo5, 1Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, 2Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, 3Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, 4Hospital Clinico San Carlos, Madrid, Spain, 5Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…
  • Abstract Number: 1558 • ACR Convergence 2021

    Therapy Based Outcomes in Patients with Multisystem Inflammatory Syndrome in Children: A Single Center Study

    Diana Villacis Nunez1, Kaitlin Jones2, Lucie Fan3, Whitney Moore2, Aysha Jabbar2, Matthew Oster4, Preeti Jaggi1 and Sampath Prahalad5, 1Emory University School of Medicine - Children's Healthcare of Atlanta, Atlanta, GA, 2Children's Healthcare of Atlanta, Atlanta, GA, 3Emory University School of Medicine, Atlanta, GA, 4Emory University School of Medicine - Sibley Heart Center/Children's Healthcare of Atlanta, Atlanta, GA, 5Emory + Children's Pediatric Institute, Atlanta, GA

    Background/Purpose: Management and outcomes of multisystem inflammatory syndrome in children (MIS-C) remain under investigation and vary by institution. This study aimed to describe the outcomes…
  • Abstract Number: 1625 • ACR Convergence 2021

    Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort

    Herman Tam1, Alison Lopez2, Mona Patel2, Jonathan Rayment3, Lori Tucker4 and Catherine Biggs5, 1Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, 2British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada, 3British Columbia Children’s Hospital, University of British Columbia, Vancouver, BC, Canada, 4BC Children's Hospital, Vancouver, BC, Canada, 5[email protected], Vancouver, BC, Canada

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a post-infectious complication of COVID-19 infection with overlapping features of Kawasaki Disease (KD) and Toxic Shock Syndrome…
  • Abstract Number: 0099 • ACR Convergence 2021

    First Results of the BELCOMID Study: BELgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)

    Kurt de Vlam1, Jeroen Geldhof2, Marie Truyens3, Joao Sabino4, Marc ferrante4, Jo Lambert3, Hilde lapeere3, Tom hillary4, an Van Laethem4, Triana Lobaton3, severine vermeire4, Barbara Neerinckx1 and Patrick Verschueren5, 1University Hospitals Leuven, Leuven, Belgium, 2University Hospital Gent, Gent, Belgium, 3university hospital gent, gent, 4university hospitals leuven, leuven, 5University Hospitals Leuven - KULeuven, Leuven, Belgium

    Background/Purpose: It has been suggested that 100% of SARS-CoV2 infections leads to development of specific IgG antibodies that remain detectable for a long period of…
  • Abstract Number: 1630 • ACR Convergence 2021

    Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization

    Lauren Covert1, Mara Becker2, Rebecca Sadun1 and Heather Van Mater1, 1Duke University, Durham, NC, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a recently defined post-infectious phenomena associated with coronavirus disease 2019 (COVID-19). We assessed the demographics, clinical characteristics,…
  • Abstract Number: 0235 • ACR Convergence 2021

    Are Comorbidities in Patients with Chronic Inflammatory Rheumatic Diseases Associated with Treatment Adherence to Biosimilars in a Non-medical Switch Scenario?

    Imke Redeker1, Stefan Moustakis2, Styliani Tsiami2, Xenofon Baraliakos2, Ioana Andreica2, Bjoern Buehring2, Juergen Braun2 and Uta Kiltz2, 1German Rheumatism Research Centre (DRFZ), Berlin, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany

    Background/Purpose: The availability of biosimilars has created a financial incentive to encourage non-medical switching if cheaper products are on the market. In patients with chronic…
  • Abstract Number: 1640 • ACR Convergence 2021

    Multisystem Inflammatory Syndrome in Children at Two Tertiary Hospitals in Cape Town, South Africa: Clinical Phenotype and Distinguishing Features from Similar Acute Inflammatory Conditions

    Claire Butters1, Deepthi Abraham2, Heidi Facey-Thomas1, Debbie Abrahams1, Ayodele Faleye3, Helena Rabie2, Christiaan Scott4, Liesl Zühlke5 and Kate Webb6, 1Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, 2Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa, 3Lagos state university teaching hospital Ikeja, Lagos, Nigeria, 4University of Cape Town, Faculty of Health Science, Cape Town, South Africa, 5Paediatric Cardiology, University of Cape Town, Cape Town, South Africa, 6University of Cape Town, Cape Town, South Africa

    Background/Purpose: Distinguishing Multisystem Inflammatory Syndrome in Children (MIS-C) associated with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) from acute, pyrexial childhood illness can be challenging.…
  • Abstract Number: 0439 • ACR Convergence 2021

    Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer

    Amy Cunningham-Bussel1, Jiaqi Wang2, Lauren Prisco3, Lily Martin2, Kathleen Vanni2, Alessandra Zaccardelli2, Mazen Nasrallah4, Lydia Gedmintas2, Lindsey MacFarlane5, Nancy Shadick6, Mark M. Awad7, Osama E. Rahma7, Nicole LeBoeuf8, Ellen Gravallese9 and Jeffrey Sparks2, 1Brigham and Women's, Brookline, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Pound Ridge, MA, 4MGH, Somerville, MA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham & Women's Hospital, Boston, MA, 7Dana-Farber Cancer Institute, Boston, 8Brigham and Women's Hospital, Department of Dermatology, Boston, MA, 9Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Immune-related adverse events (irAEs) are a frequent and serious complication of immune checkpoint inhibitor (ICI) treatment for cancer, which can resemble primary rheumatic diseases.…
  • Abstract Number: 0621 • ACR Convergence 2021

    Case Series of IgG4-related Disease in African American Patients at Two Large Academic Centers

    Jonathan Thaler1, Sunita Dia2 and Florina Constantinescu2, 1MedStar Georgetown University Hospital, Washington, DC, 2Medstar Washington Hospital Center, Washington, DC

    Background/Purpose: IgG4-related Disease (IgG4-rD) is a fibroinflammatory disease with highly variable manifestations that can be difficult to diagnose. Response to treatment with prednisone and/or rituximab…
  • Abstract Number: 0630 • ACR Convergence 2021

    Telemedicine in Rheumatology Care: A Systematic Review

    Lesley Jackson1, Timothy Edgil2, Brittany Hill3, Catherine H. Smith4, Jasvinder Singh1 and Maria I. Danila1, 1University of Alabama at Birmingham, Birmingham, AL, 2Division of General Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Brookwood Baptist Health, Leeds, AL, 4Lister Hill Library of the Health Sciences, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Coronavirus disease 2019 (COVID-19) pandemic led to a dramatic uptake of telemedicine in rheumatology. Given the impact of the pandemic on care delivery, we…
  • Abstract Number: 1083 • ACR Convergence 2021

    Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes in Flares During the COVID-19 Pandemic: An International Survey

    Samira Nazzar Romero1, Lakshmi Moorthy2, Jennifer Tousseau3, Sivia Lapidus4, Mariana Correia Marques5, Leanne Mansfield6, Marinka Twilt7, Grant Schulert8, Maria Gutierrez9, Saskya Angevare10, Fatma Dedeoglu11 and Karen Durrant12, 1University of California Los Angeles, Los Angeles, CA, 2Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 3Autoinflamamtory Alliance, Lincoln, CA, 4The Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Montclair, NJ, 5UPMC Children`s Hospital of Pittsburgh, Pittsburgh, PA, 6Hospital for Special Surgery, New York, NY, 7Alberta Children's Hospital, Calgary, AB, Canada, 8Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9John's Hopkins, Baltimore, MD, 10Autoinflammatory Alliance / Kaisz / ENCA as patient organizations, Amersfoort, Netherlands, 11Boston Children's Hospital, Boston, MA, 12Autoinflammatory Alliance, San Francisco, CA

    Background/Purpose: The exaggerated inflammatory responses to the SARS-CoV-2 virus and the paucity of data on COVID-19 infection risk in systemic autoinflammatory disease (SAID) patients posed…
  • Abstract Number: 0417 • ACR Convergence 2020

    Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes

    Eduardo Martin-Nares1, Janette Furuzawa-Carballeda1, Ángel Alexis Priego-Ranero1, Isela Chan-Campos1, Gladys Sulikey Herrera-Noguera1, Fidel López-Verdugo1 and Gabriela Hernandez-Molina1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Patients with IgG4-related disease (IgG4-RD) can be classified in clinical phenotypes which differ in terms of demographics, clinical and serological features. Whether there are…
  • Abstract Number: 0645 • ACR Convergence 2020

    Prevalence and Clinical Features of COVID-19 in a Large Cohort of 199 Patients with Sarcoidosis

    Anne-Claire Desbois1, Cindy Marques1, Leila Lefèvre1, Serge Barmo1, Camille Lorenzo1, Mathilde Leclercq1, Gaëlle Leroux1, Chloé Comarmond1, Catherine Chapelon-Abric1, Fanny Domont1, David Saadoun1 and Patrice Cacoub1, 1AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Paris, France

    Background/Purpose: To investigate the prevalence, clinical features and outcomes of coronavirus disease 2019 (COVID-19) among sarcoidosis patients.Methods: We retrospectively collected clinical features, treatments and outcomes…
  • Abstract Number: 1033 • ACR Convergence 2020

    Systemic Treatment in Sarcoidosis. Study of 377 Patients from a Single University Hospital

    David Martinez-Lopez1, Raul Fernandez-Ramon2, José Luis Martín-Varillas3, Lara Sanchez-Bilbao2, Inigo Gonzalez-Mazon4, Jorge Javier Gaitan-Valdizan5, Rosalia Demetrio-Pablo2, Miguel Ángel González-Gay6 and Ricardo Blanco2, 1Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Sierrallana, Torrelavega, Spain, 4Hospital Universitario Marques de Valdecilla, Bezana, Spain, 5Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Sarcoidosis is a multisystemic disease characterized by the formation of non-necrotizing granulomas. The most frequently affected organs are the lungs, skin and eyes. Systemic…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology